Vascular Therapies is a biotechnology company dedicated to enhancing patient outcomes by addressing surgical stenosis in individuals with kidney and vascular disease. Their primary focus revolves around developing innovative solutions that target this specific condition. One of their notable achievements is the creation of Sirogen™, an investigational sirolimus formulation designed for local, perivascular drug delivery.

This formulation is currently being evaluated in the ACCESS 2 clinical trial, aiming to determine its safety and efficacy in improving vascular access outcomes for hemodialysis patients aged 65 and older who require an arteriovenous fistula. Led by a highly experienced team with vast expertise in drug development and commercialization, Vascular Therapies is determined to make a difference in the field of biotechnology. Their dedicated Board of Directors consists of renowned professionals from various disciplines, including medicine, medical technology, finance, and life science investing, ensuring a well-rounded approach to their work